Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Jun;236(6):4121-4137.
doi: 10.1002/jcp.30166. Epub 2020 Nov 23.

The role of toll-like receptor 4 (TLR4) in cancer progression: A possible therapeutic target?

Bahareh Kashani  1   2 , Zahra Zandi  1   2 , Atieh Pourbagheri-Sigaroodi  3 , Davood Bashash  3 , Seyed H Ghaffari  1
Affiliations
Review

The role of toll-like receptor 4 (TLR4) in cancer progression: A possible therapeutic target?

Bahareh Kashani et al. J Cell Physiol. 2021 Jun.

Abstract

The toll-like receptor (TLR) family consists of vital receptors responsible for pattern recognition in innate immunity, making them the core proteins involved in pathogen detection and eliciting immune responses. The most studied member of this family, TLR4, has been the center of attention regarding its contributory role in many inflammatory diseases including sepsis shock and asthma. Notably, mounting pieces of evidence have proved that this receptor is aberrantly expressed on the tumor cells and the tumor microenvironment in a wide range of cancer types and it is highly associated with the initiation of tumorigenesis as well as tumor progression and drug resistance. Cancer therapy using TLR4 inhibitors has recently drawn scientists' attention, and the promising results of such studies may pave the way for more investigation in the foreseeable future. This review will introduce the key proteins of the TLR4 pathway and how they interact with major growth factors in the tumor microenvironment. Moreover, we will discuss the many aspects of tumor progression affected by the activation of this receptor and provide an overview of the recent therapeutic approaches using various TLR4 antagonists.

Keywords: cancer; immune escape; inflammation; metastasis; targeted therapy; toll-like receptor 4 (TLR4).

PubMed Disclaimer

References

REFERENCES

    1. Ahrén, I. L., Anders, B., Egesten, A., & Riesbeck, K. (2001). Lipopolysaccharide Binding protein increases toll-like receptor 4-dependent activation by nontypeable Haemophilus influenzae. The Journal of infectious diseases, 184(7), 926-930.
    1. Avila, M., Martinez-Juarez, A., Ibarra-Sanchez, A., & Gonzalez-Espinosa, C. (2012). Lyn kinase controls TLR4-dependent IKK and MAPK activation modulating the activity of TRAF-6/TAK-1 protein complex in mast cells. Innate Immunity, 18(4), 648-660.
    1. Awasthi, S., Singh, B., Ramani, V., Xie, J., & Kosanke, S. (2019). TLR4-interacting SPA4 peptide improves host defense and alleviates tissue injury in a mouse model of Pseudomonas aeruginosa lung infection. PLoS One, 14(1):e0210979.
    1. Basu, S., Pathak, S. K., Chatterjee, G., Pathak, S., Basu, J., & Kundu, M. (2008). Helicobacter pylori protein HP0175 transactivates epidermal growth factor receptor through TLR4 in gastric epithelial cells. Journal of Biological Chemistry, 283(47), 32369-32376.
    1. Bayraktar, R., & Calin, G. A. (2019). The interaction between two worlds: microRNAs and Toll-like receptors. Frontiers in Immunology, 10, 1053.

LinkOut - more resources